AUTHORS
Francesca Castro, MS, RD, CSO, Andriy Derkach, PhD2, Teng Fei, PhD3, Nandhini Iyer, MD4, Mirae Baichoo, PhD5, Sridevi Rajeeve, MD6, Jeannen Santos, MS7, Tara Sood, RN8, David Manrique9, Katrina Hartog, MPH, RD, CDN10, Ethan Tse, PhD Canidate11, Ed Reznik, PhD12, Kylee Maclachlan, MD, PhD13, Hamza Hashmi, M.D.14, Carlyn Rose Tan, MD15, Neha Korde, MD16, Malin Hultcrantz, MD PhD17, Maximilian Merz, MD18, Francesco Maura, MD19, Hani Hassoun, MD20, Parastoo B. Dahi, MD21, Gunjan L. Shah, MD, MS22, Heather J. Landau, MD23, Sergio Giralt, MD24, Jonathan Peled, MD/PhD25, Sham Mailankody, MBBS26, Saad Z. Usmani, MD27, Alexander M. Lesokhin, MD28, Urvi A. Shah, MD, MS, DipABLM29
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Loyola University, Chicago, Illinois, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 State University of New York System Downstate Health Sciences University, Brooklyn, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York, New York, United States
29 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction
In multiple myeloma (MM), while lenalidomide (len) maintenance has significantly improved survival, toxicities like diarrhea impair adherence in some patients. Additionally, microbiome composition, especially butyrate producers, correlates with response and gastrointestinal toxicity (Shah et al CCR 2022; Miller et al CCR 2026). Thus, alternatives like daratumumab (dara) warrant exploration.
Our prospective trial (NCT04497961) in 89 patients with newly diagnosed MM with or without transplant showed comparable efficacy rates for subcutaneous dara vs len (Rajeeve et al ASH 2025). However, the effects of dara vs len on the microbiome have not been studied.
As MM survivors live longer, improving metabolic and microbiome health is critical. In our NUTRIVENTION trial, a high-fiber, plant-based diet (HFPBD) in patients with precursor plasma cell disorders with an elevated body mass index (BMI) improved metabolic and microbiome health (Shah et al Can Disc 2026). No such dietary study exists in MM survivors. We hypothesized that a HFPBD would favorably modulate metabolic and microbiome health in patients with MM receiving maintenance therapy.
Methods
To evaluate the effects of maintenance drugs on the microbiome, stool samples were collected for gut microbiome analysis (shotgun sequencing) at study baseline (BL) and annually (C13D1, C25D1). Microbiome markers (α-diversity by inverse Simpson's index, relative abundance of butyrate producers [RABP], principal coordinates analysis [PCoA1], and the Firmicutes-Bacteroidetes [FB] ratio – a higher ratio indicates dysbiosis) were compared between arms using the Wilcoxon rank-sum test at BL and C13D1.
For diet evaluation, we embedded a nonrandomized HFPBD substudy (NUTRIVENTION-4) within the parent trial (NUTRIVENTION-4). Up to 15 patients per arm could opt in to the substudy at C13D1 or C25D1. They received a 12-week HFPBD with 24 weeks of dietary coaching. The substudy primary endpoint was to compare changes in RABP with 12 weeks of HFPBD. Stool samples were also collected at C16D1 or C28D1 in all participants.
To assess dietary quality, the healthy eating index (HEI) was derived from annual food frequency questionnaires. Changes in HEI, BMI, cholesterol and HgbA1c were analyzed with paired t-tests over 12 weeks. Microbiome changes before and after HFPBD in substudy patients and matched timepoints in non-substudy patients were compared via the Wilcoxon signed-rank test.
Results
We evaluated the effects of dara vs len on the microbiome. At BL (n=69), there was no difference in RABP (p=0.65), α-diversity (p=0.18), FB ratio (p=1.00), and PCoA1 (p=0.25). However, at C13D1 after a year on maintenance (n=62) patients on dara (n=29) had higher median RABP (15.5% vs 6.4%; p=0.01), α-diversity (p=0.01) and PCoA1 (p<0.001) compared to patients on len (n=33). Faecalibacterium prausnitzii, a butyrate producer, had the highest correlation with PCoA1 (Pearson correlation = 0.58).
We also evaluated the effects of diet on microbiome and metabolism during maintenance therapy and 24 patients (dara [n=15] and len [n=9]) enrolled in the HFPBD substudy. The median age was 58.5 years, 91% with BMI >25kg/m2, 54% female and 33% Black, Hispanic, or other.
All patients completed the substudy. They had increase in median HEI scores from before HFPBD to 1 year after (63 vs 72; p=0.049). There was a median reduction in BMI (-4.6%; p<0.001), HgbA1c (p<0.001), total and LDL cholesterol (p=0.01) at W12.
In paired samples from substudy patients (n=19) there was a reduction in median FB ratio (p=0.010), increase in RABP (7.7% to 13%; p=0.005) and PCoA1 (p=0.001). At matched timepoints, non-substudy patients (n=26) showed no changes in FB ratio (p=0.39), RABP (p=0.94) and PCoA1 (p=0.53).
Further dietary, microbiome, metabolic and immune analyses are ongoing and will be presented at the meeting.
Conclusions
This is the first and largest study to evaluate maintenance drug and dietary effects on microbiome and metabolic health in MM survivors. After one year on maintenance, len was associated with less favorable microbiome changes such as lower butyrate producers and α-diversity when compared to dara. A HFPBD increased microbiome butyrate producers as well as improved metabolic health in participants on the substudy at 12 weeks. These benefits were not seen in the non-substudy arm. These findings support a randomized trial to assess dietary impact on clinical outcomes in MM (NUTRIVENTION-5; NCT07226609; recruiting).
DISCLOSURES
Urvi A. Shah, MD, MS, DipABLM: Sanofi - Honoraria; Janssen - Honoraria; i3Health - Honoraria; Bristol Myers Squibb - Research Funding; Sabinsa - Research Funding; Janssen - Research Funding; M and M labs - Research Funding